Xenon Pharmaceuticals Stock Today
| XENE Stock | USD 38.52 1.10 2.78% |
Performance0 of 100
| Odds Of DistressLess than 46
|
Xenon Pharmaceuticals is trading at 38.52 as of the 19th of January 2025, a 2.78 percent decrease since the beginning of the trading day. The stock's lowest day price was 38.43. Xenon Pharmaceuticals has 46 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 19th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of November 2014 | Category Healthcare | Classification Health Care |
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. The company has 76.24 M outstanding shares of which 3.48 M shares are at this time shorted by private and institutional investors with about 7.75 trading days to cover. More on Xenon Pharmaceuticals
Moving against Xenon Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Xenon Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | James Empfield | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsXenon Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Xenon Pharmaceuticals' financial leverage. It provides some insight into what part of Xenon Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Xenon Pharmaceuticals (XENE) is traded on NASDAQ Exchange in USA. It is located in 3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8 and employs 251 people. Xenon Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.02 B. Xenon Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 76.24 M outstanding shares of which 3.48 M shares are at this time shorted by private and institutional investors with about 7.75 trading days to cover.
Xenon Pharmaceuticals currently holds about 788.24 M in cash with (145.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.66.
Check Xenon Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Xenon Pharmaceuticals outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Xenon Pharmaceuticals to benefit from reduced commissions. Consequently, other corporate entities are subject to a different set of regulations than regular investors in Xenon Pharmaceuticals. Please pay attention to any change in the institutional holdings of Xenon Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.
Check Xenon Ownership Details
Xenon Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Adage Capital Partners Gp Llc | 2024-09-30 | 2.1 M | |
| Pictet Asset Manangement Sa | 2024-09-30 | 1.5 M | |
| T. Rowe Price Investment Management,inc. | 2024-09-30 | 1.5 M | |
| Alliancebernstein L.p. | 2024-09-30 | 1.4 M | |
| Rock Springs Capital Management Lp | 2024-09-30 | 1.3 M | |
| Marshall Wace Asset Management Ltd | 2024-09-30 | 1.2 M | |
| First Light Asset Management, Llc | 2024-09-30 | 1.2 M | |
| Affinity Asset Advisors, Llc | 2024-09-30 | 1.1 M | |
| Samlyn Capital, Llc | 2024-09-30 | 1 M | |
| Fmr Inc | 2024-09-30 | 6.9 M | |
| Venbio Select Advisor Llc | 2024-09-30 | 5.7 M |
Xenon Pharmaceuticals Historical Income Statement
Xenon Stock Against Markets
Xenon Pharmaceuticals Corporate Management
| Robin Sherrington | Sr. VP of Bus. and Corporate Devel. | Profile | |
| CMA CPA | CEO Pres | Profile | |
| MBA MPH | Chief Officer | Profile | |
| Sherry Aulin | Chief Officer | Profile | |
| Christopher MD | Chief Officer | Profile | |
| Andrea JD | Chief Secretary | Profile | |
| MBA MSc | Ex Operations | Profile |
Already Invested in Xenon Pharmaceuticals?
The danger of trading Xenon Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Xenon Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Xenon Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Xenon Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenon Pharmaceuticals. If investors know Xenon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Xenon Pharmaceuticals is measured differently than its book value, which is the value of Xenon that is recorded on the company's balance sheet. Investors also form their own opinion of Xenon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xenon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xenon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.